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 Financiación de la I+D+i en Salud Mental y 
Neurociencias en H2020 
– Oportunidades en Pilares 1, 2 y 3 
 
 Oportunidades en la Iniciativa de Medicamentos 
Innovadores (IMI2) 
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Future and Emerging Technologies (FET) 
Call - FET Proactive – Boosting emerging technologies  
 H2020-FETPROACT-2016-2017  
 


















































































































 Strategic investments in key 
technologies (e.g. advanced 
manufacturing, micro-
electronics) underpin innovation 
across existing and emerging 
sectors. 
 Europe needs to attract more 
private investment in research 
and innovation. 
 Europe needs more innovative 










































Pilar 2 – Liderazgo Industrial 
  
1) Leadership in enabling & industrial technologies (LEITs) 13.781 Mio. € 
               
              1.1 ICT (w/o E-health) 7.939 Mio. € 
              1.2, 1.3 y 1.5: Nanotech., materials and production 3.797 Mio. € 
              1.4 Biotechnology 509 Mio. (from FP7-Health)  
              1.6 Space 1.536 Mio. € 
 
2) Access to Risk Finance 3.538 Mio. €  
 
3) Innovation in SMEs  619 M€ 




































Pilar 3 – Retos Sociales 
  
 
 Concerns of citizens and 
society/EU policy objectives 
(climate, environment, energy, 
transport etc) cannot be achieved 
without innovation.  
 Breakthrough solutions come 
from multi-disciplinary 
collaborations, including social 
sciences & humanities. 
 Promising solutions need to be 




































El Reto Social 1 “Salud, Cambio Demográfico y Bienestar” 
  
• Ageing population  
 
• Understanding disease – personalised 
medicine 
 
• Chronic and infectious disease burden 
 
• Drug development 
 
• Well informed patients put higher demands 
on healthcare providers  
 







































Topics SC1 (2016-2017) 
1.1 Understanding health, well-being and disease (4 topics) 
 
 SC1-PM-01-2016:  Multi omics for personalised therapies addressing diseases of the immune  
  system 
 SC1-PM-02-2017:  New concepts in patient stratification  
 SC1-PM-03–2017:  Diagnostic characterisation of rare diseases 
 SC1-PM-04–2016:  Networking and optimising the use of population and patient cohorts at EU  
  level  
 
1.2. Preventing disease (3 topics) 
 
 SC1-PM-05–2016:  The European Human Biomonitoring Initiative  
 SC1-PM-06–2016:  Vaccine development for malaria and/or neglected infectious diseases  



















































































































































































Topics SC1 (2016-2017) 
1.3 Treating and managing diseases: (4 topics) 
 
 SC1-PM-08–2017:  New therapies for rare diseases  
 SC1-PM-09–2016:  New therapies for chronic diseases  
 SC1-PM-10–2017:  Comparing the effectiveness of existing healthcare interventions in the adult 
  population  
 SC1-PM-11–2016-2017: Clinical research on regenerative medicine  
 
 
1.4 Active ageing and self-management of health: (4 topics) 
 SC1-PM-12–2016:  PCP - eHealth innovation in empowering the patient  
 SC1-PM-13–2016:  PPI for deployment and scaling up of ICT solutions for active and healthy  
  ageing  
 SC1-PM-14–2016:  EU-Japan cooperation on Novel ICT Robotics based solutions for active and  
  healthy ageing at home or in care facilities  




































Topics SC1 (2016-2017) 
1.5 Methods and data: (5 topics ) 
 SC1-PM-16 - 2017:  In-silico trials for developing and assessing biomedical products  
 SC1-PM-17 - 2017:  Personalised computer models and in-silico systems for well-being  
 SC1-PM-18 - 2016:  Big Data supporting Public Health policies  
 SC1-PM-19 - 2017:  PPI for uptake of standards for the exchange of digitalised healthcare records 
 SC1-PM-20 - 2017:  Development of new methods and measures for improved economic  
  evaluation and efficiency measures in the health sector  
 
1.6 Health care provision and integrated care:  
 SC1-PM-21 - 2016:  Implementation research for scaling-up of evidence based innovations and  





































Topics SC1 (2016-2017) 
Co-ordination activities: (15 topics, 1 ERA Net) 
 SC1-HCO-01 - 2016:  Valorisation of FP7 Health and H2020 SC1 research results  
 SC1-HCO-02 - 2016:  Standardisation of pre-analytical and analytical procedures for in vitro  
  diagnostics in personalised medicine  
 SC1-HCO-03 - 2017:  Implementing the Strategic Research Agenda on Personalised Medicine (ERA-Net) 
 SC1-HCO-04 - 2016:  Towards globalisation of the Joint Programming Initiative on Antimicrobial  
  Resistance  
 SC1-HCO-05 - 2016:  Coordinating personalised medicine research  
 SC1-HCO-06 - 2016:  Towards an ERA-NET for building sustainable and resilient health system models 
 SC1-HCO-07 - 2017:  Global Alliance for Chronic Diseases (GACD) 
 SC1-HCO-08 - 2017:  Actions to bridge the divide in European health research and innovation  
 SC1-HCO-09 - 2016:  Support for Europe’s leading Health ICT SMEs  
 SC1-HCO-10 - 2016:  Coordinated Action to support the recognition of Silver Economy  
  opportunities arising from demographic change  
 SC1-HCO-11 - 2016:  Digital health literacy   
 SC1-HCO-12 - 2016:  EU-US interoperability roadmap  
 SC1-HCO-13 - 2016:  EU eHealth Interoperability conformity assessment  





































   
Topics SC1 (2016-2017) 
Other Actions:  
 1. Subscription fee: Human Frontier Science Programme Organisation  
 2. InnovFin Infectious Diseases (InnovFin ID) Pilot  
 3. First interim evaluation of the EDCTP2 programme  
 4. First interim evaluation of the IMI2 programme  
 5. European registry for human embryonic stem cell lines  
 6. Studies, activities of the Scientific Panel for Health, and for conferences, events and    
 outreach activities 
 7. External expertise 
 8. Horizon Price on reducing maternal and new-born morbidity and mortality – the    
dsBirth Day Prize  
 9. Grant to the Global Alliance for Chronic Diseases  
 10. Expert group for alternatives to animal testing  
 11. Presidency events – eHealth 
 12. Establishing EU mHealth hub including evidence for the integration of mHealth in  





































Tabla de fechas 





SC1-PM-12 / 13 / 18 
SC1-HCO-10 / 11 / 12 / 








SC1-PM-01 / 04 / 05 / 


















SC1-PM-03 / 20 
SC1-HCO-03 / 07 / 08 
11.04.2017 
SC1-PM-15 20.09.2016 31.01.2017 




































Presupuesto para SC1 conv. 2016-2017 
• Approx. € 400 M. (2016) y € 350 M. (2017) (línea 
presupuestaria de DG-RTD)  
 
• Approx. € 100 M. (2016) y € 87 M. (2017) (línea 
presupuestaria DG-CNECT)  
 





































Tasas de financiación 
 
100% costes directos, 25% costes indirectos, excepto: 
 
 SC1-PM-13–2016, SC1-PM-19–2017   
– The funding rate for PPI actions is limited to 35% of the total eligible 
costs to leverage co-financing from the procurers in this specific case.  
 
  
 SC1-PM-12–2016   
– The funding rate for PCP actions is limited to 90% of the total eligible 





































Work Programme 2016 – 2017: SC6 
Europe in a changing world- inclusive, 
innovative and reflective societies 
Prizes 
 
Horizon Prize for Social Innovation in Europe 
  
Specific challenge to be addressed (2 Million) 
EC  (in cooperation with the European Investment Bank Institute) has 
invited citizens to "vote" through an easy to use on-line system, among 
5 different objectives: 
 
• Obesity in children 
• Aging population 
• Immigrants 
• Women 
• Clean energy 
 
 













































SC7 Secure societies – Protecting freedom and security of 
Europe and its citizens  
 
 Call - Digital Security Focus Area 
 
• DS-03-2016: Increasing digital security of health related data on a systemic 
level 
 
RIA single-stage evaluation 




































Oportunidades en SC6 
SC6. Europe in a changing world- inclusive, innovative  
and reflective societies 
Prizes 
 
Horizon Prize for Social Innovation in Europe 
  
 Specific challenge to be addressed (2 Million) 
 EC  (in cooperation with the European Investment Bank Institute) has invited 
citizens to "vote" through an easy to use on-line system, among 5 different 
objectives: 
 
• Obesity in children 
• Aging population 
• Immigrants 
• Women 
• Clean energy 
 
 


















































































SME Instrument en WP2016-2017 
SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare 
biotechnology sector 
 
a) Cell technologies in medical applications (all phase 1 and phase 2 
deadlines in 2016 and 2017) 
b) Clinical research for the validation of biomarkers and/or diagnostic 
medical devices (¡solo fase 2!) 
 
 
SMEInst-06-2016-2017 - Accelerating market introduction of ICT 






































 100% de financiación SMEInst-05-2016-2017;  
 
 70% en SMEInst-06-2016-2017 
 
 Menos bottom-up en SC1 vs otros retos 
 
 Convocatoria abierta con fechas de corte 
 
 Evaluación: 
– Fase 1: Phase 1 thresholds: 
• Excellence: 4/5 ; Impact: 4/5 ; Implementation: 4/5 
• Minimum overall threshold: 13/15 
• Score = Excellence + Impact *1,5 + Implementation 
– Fase 2: Phase 2 thresholds :  
• Excellence: 3/5 ; Impact: 4/5 ; Implementation: 3/5  
• Minimum overall threshold: 12/15  










































Calendario de fechas de corte para el SME Instrument 
2016 2017 
Fase I Fase II Fase I Fase II 
24 feb. 3 feb. 15 feb. 18 enero 
3 mayo 14 abril 3 mayo 6 abril 
7 sept. 15 junio 6 sept. 1 junio 




































Fast Track to Innovation 
Condiciones de la convocatoria 
 
 For 2015 and 2016: 200 Mio € (100 + 100)  
 About 50-70 actions (projects) will be funded / year  
 Grants for up to 3 Mio € possible (maximum!)  
 
 -> approximately 20 actions per Cut-off to be funded for all themes 
(bottom-up!)  
 




































Actividades a financiar 
 
 Advanced and specific research and development  
 Advanced performance testing  
 Piloting  
 Demonstration activities  
 Final validation of a system in the operational environment  
 Business model validation  
 Marketing activities (not purely commercial)  
 Activities for strategic commercial and technical relevance 
 
 Level of development:  
 Technology readiness level (TRL)  
 TRL 6 -> TRL 9 in very short time frame  













































































• ERC-IDEAS: 13.268 M€ (presupuesto duplicado frente a PM7)    
• Más enfocado jóvenes investigadores e investigación     
básica, pero  
• Sin olvidar la visión sobre el impacto de la investigación! 
 
•  FET (Tecnologías Futuras y Emergentes): 3.100 M€ 
 - Las TIC como herramientas para alcanzar objetivos  
 
• Marie Sklodowska Curie (Movilidad): 5.752 M€ 
   
• Infraestructures (ESFRI): 2.478  M€ (x2 en comparación con PM7) 
• Instrumento para avanzar en el Espacio Europeo de 
Investigación (ERA) 




































Posibles topics relacionados con biomedicina en 







































 Financiación de la I+D+i en Salud Mental y 
Neurociencias en H2020 
– Oportunidades en Pilares 1, 2 y 3 
 
 Oportunidades en la Iniciativa de Medicamentos 
Innovadores (IMI2) 
 

















































































Abierta la 6ª convocatoria de IMI 2 
  
Call topics 
 Development of Quantitative System Toxicology (QST) approaches 
to improve the understanding of the safety of new medicines 
 Establishing impact of RSV (respiratory syncytial virus) infection, 
resultant disease and public health approach to reducing the 
consequences 
 
Topics under the Big Data for Better Outcomes programme: 
 Real World Outcomes Across the AD (Alzheimer’s disease) Spectrum 
(ROADS) to Better Care 
 Development of an outcomes-focused platform to empower policy 








































Hacia la 7ª convocatoria de IMI2 
 http://www.imi.europa.eu/content/future-topics  
1. Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks  
2. Validation of translational imaging methods in drug safety assessment (TRISTAN)  
3. Identification of drugable targets modulating misfolded proteins in major 
neurodegenerative diseases  
4. Pathological neuron-glia interactions in neuropathic pain  
5. Dry age-related macular degeneration: development of novel clinical endpoints for 
clinical trials with a regulatory and patient access intention  
6. A comprehensive ‘paediatric preclinical POC platform’ to enable clinical molecule 
development for children with cancer  
7. Identification and validation of non-invasive markers across the spectrum of 
nonalcoholic fatty liver disease (NAFLD)  
  
Topics under the Big Data for Better Outcomes programme  
1. Coordination and support action (CSA) for the big data for better outcomes 
programme  
2. Increase access and use of high quality data to improve clinical outcomes in heart 
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 Oportunidades en la Iniciativa de Medicamentos 
Innovadores (IMI2) 
 



















































































• Próxima convocatoria 2016 
• Financiación ISCIII: 500.000 € 
• Beneficiarios: 
• Topic: Estudios clínicos sobre nuevos usos terapéuticos de 
moléculas ya existentes  
• Excluido cánceres raros, infecciosas raras 
• Preanuncio el 6 de noviembre 





































 Topics 2016 (ETPN): Diagnosticos, Dianas terapéuticas y Medicina Regenerativa 
 Una fase de envío de propuestas  
 Abre el 26 de noviembre 
 Compromiso  ISCIII: 0,25 M €. Beneficiarios: Hospitales y centros 
del SNS (CIBER e IIS si coordinadores del consorcio) 
 Compromiso MINECO: 0,5 M €. Beneficiarios: centros de I+D sin 









































• 2 socios españoles: ISCIII y MINECO 
 
Convocatoria 2015: 
• Proyectos en evaluación. Contribución MINECO: 
0,8 M€ 
• ELSA – Aspectos éticos, sociales y legales. 
Financiación ISCIII: 50.000 € 
• 2 socios españoles: ISCIII y MINECO 
 
Convocatoria 2015: 
• Proyectos en evaluación. Contribución 
MINECO: 0,8 M€ 
• ELSA – Aspectos éticos, sociales y 






































• Enero 2016 Era-net Cofund (NEURON 3) 
 Pre-anuncio: diciembre 2015 
 Lanzamiento de la convocatoria cofinanciada a principios 
de 2016 
 Topic: “Brain disorders and injuries caused by external 
insults, such as brain and spinal cord trauma, infections, 
and toxic influence” 
 Contribución ISCIII: 500.000 € 
 Contribución MINECO: 1.000.000 € 
 
Contacto: Irene Sánchez García isanchezgarcia@isciii.es 





































Las Iniciativas de Programación Conjunta - JPIs 
 Neurodegenerative Diseases/Alzheimer’s  - JPND 
 http://www.neurodegenerationresearch.eu/  
 Agriculture, food security and climate change  
 A healthy diet for a healthy life – HDHL 
 http://www.healthydietforhealthylife.eu/  
 Cultural heritage & global change 
 Urban Europe  
 Climate Knowledge  
 More Years, Better Lives – MYBL 
 http://www.jp-demographic.eu/  
 Antimicrobial Resistance – AMR 
 http://www.jpiamr.eu/  
 Water Challenges  












































































Juan E. Riese 
 
jriese@eu-isciii.es  
 
